Efficacy, Tolerability, and Safety of Direct Acting Anti-Viral (Daa) Therapies in Octogenarian Patients with Chronic Hepatitis C Infection

Volume 2 - Issue 5

Ashamalla Michael*

Received: January 29, 2020;   Published: February 06, 2020

DOI: 10.32474/CTGH.2020.02.000149

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Our greater understanding of the Hepatitis C Virus (HCV) genome has led to the development of multiple direct- acting antivirals (DAAs) which are targeted medications at specific steps of the HCV life cycle. Antiviral therapy has become the cornerstone of treatment of chronic Hepatitis C (CHC) infection. With current antiviral therapies, CHC is easily treated and can be eliminated in almost all patients. The main targets of the DAAs are the HCVencoded proteins that are vital to the replication of the virus. DAA therapies are efficacious up to 95%, tolerable, and safe with a mild side effect profile for the treatment of CHC.

Introduction| Methods| Results| Conclusion| References|